Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Last trade$1.04
Day change-$0.105 (-9.21%)
Day range$1.04 – $1.21
Volume1,659,330
Market cap$139M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$138.71M
Price / earnings
—
Price / book
1.04×
Price / sales
29.2×
EV / sales
19.95×
EV / EBITDA
-0.79×
Profitability
Earnings per share
-$1.02
Return on assets
-52.22%
Return on equity
-93.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.41×
Quick ratio
4.41×
Cash ratio
1.34×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$106.97M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FATE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$2.08M
$1.3M
$1.37M
$1.74M
$1.91M
$1.63M
$1.86M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$2.08M
$1.3M
$1.37M
$1.74M
$1.91M
$1.63M
$1.86M
Selling, general and administrative
$8.03M
$8.83M
$9.6M
$10.67M
$10.64M
$11.45M
$13.77M
$15.26M
Research and development
$24.22M
$24.39M
$24.7M
$25.43M
$25.84M
$27.43M
$29.14M
$33.61M
Total operating expenses
$32.25M
$33.22M
$34.3M
$36.09M
$36.48M
$38.88M
$42.91M
$63.61M
Operating income
-$32.25M
-$31.13M
-$33M
-$34.72M
-$34.74M
-$36.97M
-$41.28M
-$61.75M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$30.69M
-$30.16M
-$31.21M
-$32.37M
-$32.25M
-$34.07M
-$37.62M
-$52.15M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$30.69M
-$30.16M
-$31.21M
-$32.37M
-$32.25M
-$34.07M
-$37.62M
-$52.15M
Net income attributable to common shareholders
-$30.69M
-$30.16M
-$31.21M
-$32.37M
-$32.25M
-$34.07M
-$37.62M
-$52.15M
EBITDA
-$29.57M
-$28.35M
-$30.08M
-$31.66M
-$31.51M
-$33.69M
-$37.95M
-$42.2M
Basic earnings per share
-$0.25
-$0.25
-$0.26
-$0.27
-$0.27
-$0.29
-$0.32
-$0.44
Diluted earnings per share
-$0.25
-$0.25
-$0.26
-$0.27
-$0.27
-$0.29
-$0.32
-$0.44
Recent news
Company coverage with links to the original publishers.
Fate Therapeutics announced the appointment of Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to lead commercialization of its CAR T-cell therapies. Harrell brings over 25 years of commercial leadership experience, including expertise in launching first-in-class autoimmune therapies and establishing lupus treatments. He will oversee commercial strategy for FT819 (in Phase 2 RECLAIM-LN trial for lupus nephritis) and FT839 (Phase 1/2 trial for autoimmune indications), with focus on enabling outpatient administration in community settings.
Fate Therapeutics announced that management will participate in two major investor conferences in Q4 2026: the Jefferies Global Healthcare Conference in London (November 16-19) and the Piper Sandler 38th Annual Healthcare Conference in New York (December 1-3). Live webcasts will be available on the company's investor website.
Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026. The presentations will showcase clinical data for FT819, including administration without conditioning chemotherapy and outpatient administration capabilities, as well as updates on the Phase 1/2 COMPLETE Trial for FT839, a dual-CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases.
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.
The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.